Evicenter
Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection
Manufacturer
Gilead Sciences, Inc.
Prescribing information
Biktarvy (opens in a new tab)
Questions
57
Last updated

All questions

Clinical trials: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection

13 questions · 6 sources

Study 1489

How does Biktarvy compare with abacavir/dolutegravir/lamivudine in adults starting HIV treatment (Study 1489)?

“Table 14 Virologic Outcomes of Randomized Treatment in Trials 1489 and 1490 at Week 144a in Adults with No Antiretroviral Treatment History Trial 1489 Trial 1490 BIKTARVY (N=314) ABC/DTG/3TC (N=315) BIKTARVY (N=320) DTG + FTC/TAF (N=325) HIV-1 RNA < 50 copies/mL 82% 84% 82% 84% Treatment Difference (95% CI) BIKTARVY vs. Comparator -2.6% (-8.5% to 3.4%) -1.9% (-7.8% to 3.9%) HIV-1 RNA ≥ 50 copies/mLb 1% 3% 5% 3% No Virologic Data at Week 144 Window 18% 13% 13% 13% Discontinued Study Drug Due to AE or Deathc 1% 2% 3% 3% Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA <50 copies/mLd 16% 11% 11% 9% Missing Data During Window but on Study Drug 1% <1% 0% 1% a. Week 144 window was between Day 967 and 1050 (inclusive). b. Includes participants who had ≥ 50 copies/mL in the Week 144 window; participants who discontinued early due to lack or loss of efficacy; participants who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL. c. Includes participants who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window. d. Includes participants who discontinued for reasons other than an AE, death, or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.” (opens the source at this quote in a new tab)

Note: Each row of Table 14 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1489), then BIKTARVY and DTG + FTC/TAF (Trial 1490). The Week 48 primary endpoint results appear as charts on the treatment-naive page and are not quoted here.

Study 1490

How does Biktarvy compare with dolutegravir plus emtricitabine/tenofovir alafenamide in adults starting treatment (Study 1490)?

“Table 14 Virologic Outcomes of Randomized Treatment in Trials 1489 and 1490 at Week 144a in Adults with No Antiretroviral Treatment History Trial 1489 Trial 1490 BIKTARVY (N=314) ABC/DTG/3TC (N=315) BIKTARVY (N=320) DTG + FTC/TAF (N=325) HIV-1 RNA < 50 copies/mL 82% 84% 82% 84% Treatment Difference (95% CI) BIKTARVY vs. Comparator -2.6% (-8.5% to 3.4%) -1.9% (-7.8% to 3.9%) HIV-1 RNA ≥ 50 copies/mLb 1% 3% 5% 3% No Virologic Data at Week 144 Window 18% 13% 13% 13% Discontinued Study Drug Due to AE or Deathc 1% 2% 3% 3% Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA <50 copies/mLd 16% 11% 11% 9% Missing Data During Window but on Study Drug 1% <1% 0% 1% a. Week 144 window was between Day 967 and 1050 (inclusive). b. Includes participants who had ≥ 50 copies/mL in the Week 144 window; participants who discontinued early due to lack or loss of efficacy; participants who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL. c. Includes participants who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window. d. Includes participants who discontinued for reasons other than an AE, death, or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.” (opens the source at this quote in a new tab)

Note: Each row of Table 14 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1489), then BIKTARVY and DTG + FTC/TAF (Trial 1490). The Week 48 primary endpoint results appear as charts on the treatment-naive page and are not quoted here.

Treatment-naive subgroups

Does Biktarvy work when starting treatment with a high viral load or low CD4 count?

Note: The subgroup suppression rates appear as charts on the treatment-naive page and are not quoted here.

Resistance

Has resistance to Biktarvy developed in clinical trials?

Does Biktarvy work in virologically suppressed people with the M184V/I mutation who switch to it?

Note: The second and third excerpts are from the BRAAVE section of the virologically suppressed page. The pooled virologic response rates appear as charts on that page and are not quoted here.

Study 1844

Does Biktarvy keep HIV suppressed after a switch from abacavir/dolutegravir/lamivudine (Study 1844)?

Note: Each row of Table 15 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1844), then BIKTARVY and the ATV- or DRV-based regimen (Trial 1878). Under the M=E analysis, the Week 168 result covers the 14 participants with data at that visit; 524 participants entered the extension.

Study 1878

Does Biktarvy keep HIV suppressed after a switch from boosted atazanavir or darunavir (Study 1878)?

Note: Each row of Table 15 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1844), then BIKTARVY and the ATV- or DRV-based regimen (Trial 1878).

Study 4030

Does Biktarvy keep HIV suppressed after a switch from dolutegravir plus emtricitabine/tenofovir alafenamide (Study 4030)?

Study 1961

Is switching to Biktarvy effective in virologically suppressed women (Study 1961)?

Note: The Week 48 virologic response rates appear as a chart on the virologically suppressed page and are not quoted here.

Study 4449

Is switching to Biktarvy effective in adults aged 65 and older (Study 4449)?

Note: The site states the primary endpoint as HIV-1 RNA <50 copies/mL at Week 24; the prescribing information states it as HIV RNA >50 copies/mL at Week 48.

Study 1474

Is switching to Biktarvy effective in virologically suppressed children and adolescents (Study 1474)?

BRAAVE

Is switching to Biktarvy effective in Black American adults (BRAAVE)?

Note: The Week 24 virologic response rates appear as a chart on the virologically suppressed page and are not quoted here.

Comparative studies

Biktarvy vs Dovato (dolutegravir/lamivudine): what did the DYAD study show?

Note: In DYAD, participants on BIKTARVY were randomized to switch to DOVATO or to continue BIKTARVY.